MedPath

EFFECT OF YOGA ON PATIENTS WITH ESSENTIAL TREMOR

Phase 2
Conditions
Health Condition 1: G250- Essential tremor
Registration Number
CTRI/2023/06/053982
Lead Sponsor
Department of Swasthavritta and Yoga Faculty of Ayurveda Institute of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1 Male and female patients fulfilling diagnostic criteria of Essential Tremor (According to Task Force on Tremor of the International Parkinson and Movement Disorder Society- 2018)

2 Patients with ET of age > 18 years to 65 years

3 Patients willing to participate, with their written consent.

4 Patients able to join Yoga Session in online/offline mode.

5 Patients able to follow instructions during Yoga Session.

Exclusion Criteria

1 Patients with Essential Tremor of age < 18 years and > 65 years.

2 Patients having any atypical movement disorder (e.g., Essential Tremor in combination with Parkinsonâ??s Disease).

3 Patients with known causes of enhanced physiological tremor viz, current or recent exposure to tremorogenic drugs or presence of drug withdrawal state.

4 Patients with past history of Head Injury, Stroke, Brain or Abdominal Surgery and any abnormal Brain MRI.

5 Patients suffering from any severe disease viz, Chronic Liver disease, Chronic Renal disease, Chronic Musculo-skeletal disorders, Coronary Artery Disease, Cancer, Psychogenic Tremor etc.

6 Patients consuming Alcohol or Anti-Psychotic drugs.

7 Patients unable to complete the questionnaires.

8 Pregnant Women.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Essential Tremor severity scale (TETRAs) <br/ ><br>Essential Tremor balance scale (FULLERTON ADVANCED BALANCE SCALE) <br/ ><br>Anxiety and Depression Scale (The Hospital Anxiety and Depression Scale) <br/ ><br>Quality of Life in Essential Tremor Questionnaire (QUEST)Timepoint: The primary outcome of both groups will be assessed at 0 month (baseline), after 1 month (first follow-up), after 2 months (second follow-up), and after 3 months (post-intervention follow-up).
Secondary Outcome Measures
NameTimeMethod
CBC <br/ ><br>RBS <br/ ><br>LFT <br/ ><br>RFT <br/ ><br>Lipid ProfileTimepoint: The secondary outcome of both groups will be assessed at 0 month (baseline) and after two months (second follow-up).
© Copyright 2025. All Rights Reserved by MedPath